MEMPHIS, Tenn., May 2 /PRNewswire/ -- A commercially developed vaccine has successfully protected mice and ferrets against a highly lethal avian influenza virus, according to the investigator who led the study at St. Jude Children's Research Hospital. The vaccine was developed by Vical Incorporated of San Diego, California.
This finding, coupled with results of previous studies that showed protection against multiple human flu strains, suggests that such a vaccine would protect humans against multiple variants of the bird and human influenza viruses, according to Richard Webby, Ph.D., assistant member of Infectious Diseases at St. Jude. Such a vaccine could protect humans against an H5N1 "bird flu" virus that mutates so that it adapts to humans and can readily spread from person to person, Webby said. Influenza experts and public health officials fear that such an H5N1 variant would trigger a human pandemic (worldwide epidemic).
Webby is scheduled to present the findings of this study at the U.S. Public Health Service Professional Conference in Denver, Colo., on May 3 at 12:30 pm EDT.
The investigators used two versions of Vical's multi-component, DNA-based vaccine in the studies. One vaccine was directed against three viral proteins: NP and M2, which are "conserved" proteins that generally do not mutate quickly and therefore are slow to avoid immune responses triggered by the vaccine; and H5, a "variable" protein on the surface of the bird and human flu viruses that is critical to their ability to infect cells. This variable protein is known to mutate readily, thereby foiling previous immune responses it triggered- whether due to natural exposure or vaccination. The other version of the vaccine contained only the two conserved viral proteins.
In the St. Jude study, the full, three-component vaccine (H5, NP and M2) provided complete protection in mice against lethal challenges with a highly virulent (Vietnam/1203/2004) H5N1 avian influenza virus. Moreover, previous studies showed that a smaller version of the vaccine containing only the NP and M2 components provided significant protection against several strains of human influenza virus as well as the H5N1 "bird flu" strain.
"Such cross-protection against bird and human influenza is considered by researchers to be the 'Holy Grail' of flu vaccines," noted Webby. "By stimulating immune responses against targets not likely to mutate, the vaccine could trigger an immune defense against a broad range of variants of the virus."
"Even if the bird flu virus mutates so it becomes adapted to humans, this kind of cross protection will allow the immune system to track and attack such an emerging new variant without missing a beat," Webby said. "We wouldn't have to wait to start developing a vaccine against it until after the original virus mutated."
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital is internationally recognized for its pioneering work in finding cures and saving children with cancer and other catastrophic diseases. Founded by late entertainer Danny Thomas and based in Memphis, Tenn., St. Jude freely shares its discoveries with scientific and medical communities around the world. No family ever pays for treatments not covered by insurance, and families without insurance are never asked to pay. St. Jude is financially supported by ALSAC, its fund-raising organization. For more information, please visit www.stjude.org.
St. Jude Children's Research Hospital
CONTACT: Bonnie Kourvelas, Public Relations, +1-901-495-4815, email@example.com, or Marc Kusinitz, Ph.D., ScientificCommunications, +1-901-495-5020, or firstname.lastname@example.org, both of St.Jude Children's Research Hospital